Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

286 questions · 287 findings · 9 reviews · Airways

No studies found 20 · 7%GRADE not reported 24 · 8.4%Very low 11 · 3.8%Low 58 · 20.2%Moderate 139 · 48.4%High 35 · 12.2%

LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)

Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LABA/ICS (moderate certainty).

1 finding from 1 review

LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)

Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA probably leads to lower pneumonia: high‐risk population compared with LABA/ICS (moderate certainty).

1 finding from 1 review

LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)

Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA probably leads to lower pneumonia: low‐risk population compared with LABA/ICS (moderate certainty).

1 finding from 1 review

LABA/LAMA vs LAMA

Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA showed no clear difference in moderate to severe exacerbations: high‐risk population compared with LAMA (moderate certainty).

1 finding from 1 review

LABA/LAMA vs LAMA

Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LAMA (low certainty).

1 finding from 1 review

LABA/LAMA vs LAMA

Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA showed no clear difference in severe exacerbations: high‐risk population compared with LAMA (moderate certainty).

1 finding from 1 review